Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADAG Adagene

Trading 02-04 14:31:50 EST

2.74

-0.21

-7.12%

High3.10	Low2.74	Vol107.27K
Open2.98	D1 Closing2.95	Amplitude12.37%
Mkt Cap129.14M	Tradable Cap34.89M	Total Shares47.13M
T/O315.67K	T/O Rate0.84%	Tradable Shares12.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADAG","market":"US","secType":"STK","nameCN":"Adagene","latestPrice":2.74,"timestamp":1770233507013,"preClose":2.95,"halted":0,"volume":107265,"delay":0,"changeRate":-0.07118644067796609,"floatShares":12732488,"shares":47131300,"eps":-0.642762,"marketStatus":"Trading","change":-0.21,"latestTime":"02-04 14:31:50 EST","open":2.98,"high":3.1,"low":2.735,"amount":315667.78721700003,"amplitude":0.123729,"askPrice":2.84,"askSize":100,"bidPrice":2.75,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.642762,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"adrRate":1.25,"listingDate":1612846800000,"exchange":"NASDAQ","adjPreClose":2.95,"preHourTrading":{"tag":"盘前","latestPrice":2.94,"preClose":2.95,"latestTime":"09:29 EST","volume":101,"amount":296.860008,"timestamp":1770215399999,"change":-0.01,"changeRate":-0.00339,"amplitude":0.027119},"postHourTrading":{"tag":"盘后","latestPrice":2.95,"preClose":2.95,"latestTime":"16:10 EST","volume":4,"amount":11.8,"timestamp":1770153004444,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.668859},"requestUrl":"/m/hq/s/ADAG","defaultTab":"news","newsList":[{"id":"2606217744","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217744?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:20","pubTimestamp":1769430030,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Maze Therapeutics, Inc. (MAZE – Research Report), Adagene (ADAG –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-maze-therapeutics-inc-maze-adagene-adag-and-johnson-johnson-jnj-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-maze-therapeutics-inc-maze-adagene-adag-and-johnson-johnson-jnj-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BVYPNV92.GBP","LU0345770308.USD","XLV","SG9999001440.SGD","LU1066053197.SGD","LU1066051498.USD","BK4581","IE00BKVL7J92.USD","LU1023059063.AUD","LU0234572021.USD","BK4139","LU0058720904.USD","LU0345769631.USD","LU1244550494.USD","LU0689626769.HKD","BK4534","LU1935042991.SGD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","LU1674673428.USD","BK4588","IE00B42XCP33.USD","LU0912757837.SGD","LU0345769128.USD","LU1059921491.USD","LU1061106388.HKD","BK4137","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU0203345920.USD","LU1778281490.HKD","LU1057294990.SGD","IE0009355771.USD","MAZE","BK4007","LU2750360641.GBP","LU2592432038.USD","LU2750360997.AUD","LU0203347892.USD","HCSG","ADAG","LU1221951046.USD","LU2129689514.USD","LU0795875169.SGD","JNJ","LU1066051811.HKD","XBI","LU0345770993.USD","LABU","LU0234570918.USD"],"gpt_icon":0},{"id":"2606943922","title":"Adagene Reports $74.5 Million Year-End Cash and Sets 2026 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606943922","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606943922?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:03","pubTimestamp":1769411011,"startTime":"0","endTime":"0","summary":"Adagene Inc. announced a business update and provided its 2026 objectives. As of December 31, 2025, the company reported unaudited cash and cash equivalents of $74.5 million, which is anticipated to provide sufficient financial runway into late 2027. The company highlighted its progress in 2025, including a collaboration with ConjugateBio on bispecific antibody-drug conjugates  using Adagene-derived antibodies. For 2026, Adagene plans to provide a data update in Q1 from its ongoing Phase 1b/2 study of muzastotug in combination with pembrolizumab for third-line and later (3L+) microsatellite stable colorectal cancer  patients, covering 41 patients in the 10 mg/kg cohorts and 26 patients in the 20 mg/kg cohorts. The reported cash position is preliminary, unaudited, and subject to finalization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9CZvjY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","ADAG","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2605847027","title":"Press Release: Adagene Provides Business Update and 2026 Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2605847027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605847027?lang=en_us&edition=fundamental","pubTime":"2026-01-23 21:00","pubTimestamp":1769173200,"startTime":"0","endTime":"0","summary":"Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026. Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027. SAN DIEGO and SUZHOU, China, Jan. 23, 2026  -- Adagene Inc.  , a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalents of $74.5 million and provided a business update.-- Phase 1b/2 trial results with muzastotug in MSS CRC at ASCO: Shared. updated data from 10 mg/kg and 20 mg/kg cohorts at ASCO 2025,demonstrating a favorable safety profile at 10-20x times higher dosing. than first generation CTLA-4 inhibitors. Encouraging overall response. rates and durable responses suggest potential for long-term survival. -- FDA Fast Track designation for muzastotug in combination with Merck's. selection, trial design, patient population and endpoint","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","CRC","BK4022","BK4113","BK4139","BK4555","LU0456854461.SGD","BK4604","BK4213","R","BK4232","BK4585","MSS","ADAG","03160","LU0266512127.USD","BK4588","BK4099"],"gpt_icon":0},{"id":"2604116504","title":"LifeSci Capital Sticks to Their Buy Rating for Adagene (ADAG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116504?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:39","pubTimestamp":1768916350,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Adagene, with a price target of $8.00. According to TipRank...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-their-buy-rating-for-adagene-adag-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-their-buy-rating-for-adagene-adag-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG"],"gpt_icon":0},{"id":"2592932150","title":"Adagene's Muzastotug Gets FDA Fast Track in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932150","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932150?lang=en_us&edition=fundamental","pubTime":"2025-12-17 04:24","pubTimestamp":1765916664,"startTime":"0","endTime":"0","summary":"Adagene  said the US Food and Drug Administration granted Fast Track designation to its muzastotug drug in combination with Merck's  Keytruda for treating adults with microsatellite-stable metastatic colorectal cancer without active liver metastases.The designation is supported by early data showing efficacy, durable responses and safety, and allows for the possibility of a rolling review of future marketing applications, Adagene said Tuesday in a statement.Adagene plans to continue its randomized Phase 2 trial and expects a registration-enabling Phase 3 study to start in 2027.The company's shares rose 3.6% in recent Tuesday trading.Price: 1.73, Change: +0.06, Percent Change: +3.59","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2112291526.USD","IE00BLSP4452.SGD","LU1699723380.USD","LU0265550359.USD","LU1291159041.SGD","LU1974910355.USD","SG9999001176.USD","LU1069347547.HKD","LU2361044949.HKD","LU1116320737.USD","LU1585245621.USD","LU1201861249.SGD","LU0289739699.SGD","LU0980610538.SGD","LU0238689110.USD","LU0648001328.SGD","IE00BSNM7G36.USD","LU0070302665.USD","SG9999014542.SGD","LU2125154778.USD","LU0098860793.USD","IE00BBT3K403.USD","BK4550","LU2023250504.SGD","LU1066051225.USD","IE00B1BXHZ80.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0965508806.USD","LU0106261372.USD","LU1116320901.HKD","IE00BN8TJ469.HKD","SG9999002224.SGD","LU2023250843.SGD","IE00B4R5TH58.HKD","SG9999014575.USD","LU1093756168.USD","LU1023059063.AUD","LU1989772840.SGD","IE00BLSP4239.USD","LU2106854487.HKD","BK4534","SG9999015358.SGD","LU1066053197.SGD","LU1093756325.SGD","IE0009355771.USD","LU0211331839.USD","BK4139","LU0058720904.USD","BK4533","LU2324357040.USD","SGXZ57979304.SGD","LU1934455863.HKD","LU0985320562.USD","SG9999002232.USD","LU0320765646.SGD","LU0266013472.USD","LU0965509101.SGD","LU0861579265.USD","IE000M9KFDE8.USD","LU1934455277.USD","BK4007","LU1917777945.USD","LU2461242641.AUD","LU0203347892.USD","LU2089984988.USD","SG9999001440.SGD","LU1035773651.USD","SG9999013999.USD","LU0006306889.USD","IE00BJJMRZ35.SGD","SG9999015341.SGD","LU0265550946.USD","BK4559","IE00B2B36J28.USD","LU1571399168.USD","LU1066051498.USD","LU2361045086.USD","LU0477156953.USD","LU1929549753.HKD","LU2125154935.USD","IE0002141913.USD","LU1037948541.HKD","BK4588","LU1989771016.USD","LU1983299246.USD","SG9999014567.USD","SG9999001176.SGD","LU2361044865.SGD","LU1941712348.USD","LU1941712264.USD","LU1430594728.SGD","LU2360032135.SGD","BK4516","LU0965509010.AUD","LU0203345920.USD","LU1057294990.SGD","LU0320765489.SGD","LU1061106388.HKD","LU0965509283.SGD","LU0130517989.USD","LU1066051811.HKD","LU1162221912.USD","BK4585","LU1989772923.USD","LU1934455194.USD","LU1037948897.HKD","SG9999014559.SGD","LU2468319806.SGD","LU0234572021.USD","ADAG","LU0130102774.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2591981565","title":"Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981565","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981565?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:18","pubTimestamp":1765887529,"startTime":"0","endTime":"0","summary":"Dec 16 (Reuters) - Adagene Inc <978y.F>::*ADAGENE ANNOUNCES FDA FAST TRACK DESIGNATION FOR MUZASTOTUG (ADG126)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 16-DEC-202512:00:00.697 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nRSD6gmtB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"gpt_icon":0},{"id":"2591894279","title":"Adagene Reports Promising Responses for Muzastotug in Combination with Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2591894279","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591894279?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:01","pubTimestamp":1765886478,"startTime":"0","endTime":"0","summary":"Adagene Inc. has announced that its anti-CTLA-4 therapy, muzastotug , developed using the company's proprietary SAFEbody technology, has received FDA Fast Track Designation for the treatment of microsatellite stable  colorectal cancer. The company highlighted encouraging responses seen with muzastotug in combination with pembrolizumab, suggesting the potential to improve survival and quality of life for patients. Adagene stated that updated topline Phase 1b/2 clinical data will be shared in the coming months, as the program progresses towards a Phase 3 trial with overall survival as the primary endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via Globe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLs8Q0g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","ADAG","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2585902467","title":"Adagene Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2585902467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585902467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:40","pubTimestamp":1763991600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 08:40 ET (13:40 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"gpt_icon":0},{"id":"2585616664","title":"Guggenheim Initiates Coverage on Adagene With Buy Rating, $9 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2585616664","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585616664?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:08","pubTimestamp":1763986113,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Coverage on Adagene With Buy Rating, $9 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADAG"],"gpt_icon":0},{"id":"2583592562","title":"Adagene Signs Licensing Agreement With Third Arc Bio for SAFEbody Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2583592562","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583592562?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035258,"startTime":"0","endTime":"0","summary":"Adagene Inc. announced a licensing agreement with Third Arc Bio, Inc. Under the terms of the agreement, Third Arc Bio will use Adagene's SAFEbody technology platform to generate masked CD3 T cell engagers targeting unique tumor associated antigens. Third Arc Bio will have rights to research, develop, and commercialize two candidate molecules worldwide. Adagene will receive a $5 million upfront payment and may receive up to $840 million in development and commercial milestones, as well as royalties on end-user sales. Adagene also retains a no-cost option to develop and commercialize the candidate molecules in Greater China, Singapore, and South Korea.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9TX7Sx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","NDAQ","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","ADAG","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2579546872","title":"Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2579546872","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579546872?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908400,"startTime":"0","endTime":"0","summary":"Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based onprevious alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178218/0/en/Adagene-Announces-First-Patient-Dosed-in-Randomized-Dose-Optimization-Cohort-of-the-Phase-2-Study-of-Muzastotug-ADG126-in-Combination-with-KEYTRUDA-pembrolizumab-in-Microsatellite-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014567.USD","BK4559","SGXZ57979304.SGD","BK4588","LU0058720904.USD","SG9999001176.USD","LU1934455194.USD","SG9999002224.SGD","IE00BLSP4239.USD","IE0009355771.USD","SG9999014559.SGD","LU1941712264.USD","LU1066053197.SGD","ORR","MRK","BK4139","SG9999014542.SGD","LU1983299246.USD","SG9999015341.SGD","MSS","LU1934455863.HKD","PFS","LU0265550359.USD","LU1035773651.USD","CRC","LU1291159041.SGD","OS","BK4550","LU1934455277.USD","LU0106261372.USD","ADAG","LU1061106388.HKD","LU1430594728.SGD","LU1989772923.USD","LU0211331839.USD","LU0238689110.USD","SOC","LU1929549753.HKD","IE00B4R5TH58.HKD","LU1974910355.USD","LU1066051811.HKD","IE00BJT1NW94.SGD","SG9999002232.USD","LU1989772840.SGD","LU0266512127.USD","SG9999001176.SGD","IE00BN8TJ469.HKD","BK4097","LU0203347892.USD","LU0965509010.AUD"],"gpt_icon":0},{"id":"2578462286","title":"Adagene’s Innovative Cancer Study: A Potential Game-Changer in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2578462286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578462286?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:19","pubTimestamp":1761589191,"startTime":"0","endTime":"0","summary":"Adagene, Inc. (($ADAG)) announced an update on their ongoing clinical study. Study Overview: Adagene, Inc. (ADAG) is conducting a Phase 1b/2 clinic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagenes-innovative-cancer-study-a-potential-game-changer-in-oncology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagenes-innovative-cancer-study-a-potential-game-changer-in-oncology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2568047278","title":"Adagene Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2568047278","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568047278?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:31","pubTimestamp":1758198660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 18, 2025 08:31 ET (12:31 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4551","ADAG","LCID","BK4139","BK4596","BK4099"],"gpt_icon":0},{"id":"2568471818","title":"Adagene initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2568471818","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568471818?lang=en_us&edition=fundamental","pubTime":"2025-09-18 19:10","pubTimestamp":1758193828,"startTime":"0","endTime":"0","summary":"Lucid Capital initiated coverage of Adagene (ADAG) with a Buy rating and $9 price target Adagene is a clinical-stage biotechnology company focused ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4555","LCID","BK4596","BK4099","ADAG","BK4139","BK4551"],"gpt_icon":0},{"id":"2567073661","title":"Adagene expands SAFEbody collaboration, license agreement with Exelixis","url":"https://stock-news.laohu8.com/highlight/detail?id=2567073661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567073661?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:05","pubTimestamp":1758024319,"startTime":"0","endTime":"0","summary":"Adagene (ADAG) announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-expands-safebody-collaboration-license-agreement-with-exelixis-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-expands-safebody-collaboration-license-agreement-with-exelixis-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4139","BK4532","EXEL"],"gpt_icon":0},{"id":"2567102421","title":"Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2567102421","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567102421?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:00","pubTimestamp":1758024000,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, Sept.  16, 2025  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Un","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/16/3150716/0/en/Adagene-Expands-SAFEbody-Collaboration-and-License-Agreement-with-Exelixis-to-Develop-Third-Novel-Masked-Antibody-Drug-Conjugate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","ADC","BK4139","BK4080","BK4213","MSS","EXEL","LU0456854461.SGD","ADAG","CRC","BK4113","BK4231","LU0266512127.USD"],"gpt_icon":0},{"id":"2565656652","title":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2565656652","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565656652?lang=en_us&edition=fundamental","pubTime":"2025-09-05 21:55","pubTimestamp":1757080526,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire  on September 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLbxCv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4588","BK4585","LU0314104364.USD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2564396930","title":"Press Release: Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2564396930","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564396930?lang=en_us&edition=fundamental","pubTime":"2025-09-03 21:05","pubTimestamp":1756904700,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, Sept. 03, 2025  -- Adagene Inc.  , a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.Dr. Hoos received his M.D. in Medicine from Heidelberg University, and his Ph.D. in Molecular Oncology from the German Cancer Research Center . He trained in general surgery at the Technical University of Munich and as a fellow in cancer research at Memorial Sloan-Kettering Cancer Center and is an alumnus of the Program for Leadership Development at Harvard Business School.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","BK4588","BK4022","03160","BK4113","BK4139","BK4585","MSS","CRC","BK4604","BK4213","ADAG","BK4555","R","TM","BK4232","LU0266512127.USD","BK4099","BMS"],"gpt_icon":0},{"id":"2562351697","title":"Adagene Inc. to Participate in Investor Conferences in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2562351697","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562351697?lang=en_us&edition=fundamental","pubTime":"2025-08-26 20:05","pubTimestamp":1756209936,"startTime":"0","endTime":"0","summary":"Adagene Inc. announced its participation in upcoming investor conferences in New York. The company's Chief Strategy Officer, Mickael Chane-Du, will engage in one-on-one investor meetings and a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10. The events will feature discussions on Adagene's innovative antibody-based therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire  on August 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL2ZlJhd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","IE00BKPKM429.USD","LU2210150020.SGD","ADAG","BK4112","IE00BGHQF748.EUR","BK4588","NDAQ","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","LU0314104364.USD"],"gpt_icon":0},{"id":"2559711919","title":"Adagene Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2559711919","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559711919?lang=en_us&edition=fundamental","pubTime":"2025-08-15 19:38","pubTimestamp":1755257880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 15, 2025 07:38 ET (11:38 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1847},{"period":"1month","weight":0.6033},{"period":"3month","weight":0.9667},{"period":"6month","weight":0.3532},{"period":"1year","weight":0.5445},{"period":"ytd","weight":0.5608}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Their platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity. These features enable their novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. They have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Their platform is designed to enable the rapid development of precision immunotherapy candidates, through the identification of predictive biomarkers for patient stratification and preselection.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.330237},{"month":2,"riseRate":0.4,"avgChangeRate":-0.075434},{"month":3,"riseRate":0,"avgChangeRate":-0.224239},{"month":4,"riseRate":0.2,"avgChangeRate":-0.086636},{"month":5,"riseRate":0.6,"avgChangeRate":0.052249},{"month":6,"riseRate":0.6,"avgChangeRate":-0.017271},{"month":7,"riseRate":0.4,"avgChangeRate":-0.053125},{"month":8,"riseRate":0.6,"avgChangeRate":0.014607},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076447},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090108},{"month":11,"riseRate":0.6,"avgChangeRate":0.034268},{"month":12,"riseRate":0.4,"avgChangeRate":0.020923}],"exchange":"NASDAQ","name":"Adagene","nameEN":"Adagene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adagene,ADAG,Adagene股票,Adagene股票老虎,Adagene股票老虎国际,Adagene行情,Adagene股票行情,Adagene股价,Adagene股市,Adagene股票价格,Adagene股票交易,Adagene股票购买,Adagene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction